Practical SolutionsEvidence for what works

Frame side-effect warnings so patients keep taking their blood-pressure drugs

A one-page script changes how nurses and pharmacists describe common side effects (most are mild, and most feelings of "side effects" occur equally on a dummy pill), to cut the share of patients who stop treatment.

Proposed combination, not yet trialled as one Every source verified Health · checked 2026-11-18

What is new

Taken from: statin trials in high-income countries that measured the nocebo effect.

Applied to: primary-care hypertension programmes in low- and middle-income countries.

Blinded n-of-1 and trial-extension studies of statins found that most symptoms people report on treatment also appear on a dummy pill, and that unblinded patients report more. Telling people what to expect shapes what they feel (the nocebo effect). Stopping treatment because of feared side effects is a major reason blood pressure stays uncontrolled; a framing script costs almost nothing to add to a protocol that already exists.

The parts are supported by the studies below. The combination is a hypothesis, which is why the first test below is designed to be able to fail.

Evidence for each part

Every source, checked against the Crossref register of published papers
SourceWhat it showsRoleCheck
Wood et al., New England Journal of Medicine, 2020 doi:10.1056/nejmc2031173In a blinded n-of-1 trial, symptom intensity was nearly the same on statin and on placebo and much lower in months with no tablet: almost the whole increase appeared on the dummy pill too (figures are in the paper body, not its abstract).size of the nocebo effecttitle and year found
Gupta et al., The Lancet, 2017 doi:10.1016/s0140-6736(17)31075-9Muscle symptoms were reported 41% more often on statin when patients knew they were taking it, and not more often when blinded.unblinded patients report moretitle and year found; quoted figure 41 found in the abstract
Colloca and Barsky, New England Journal of Medicine, 2020 doi:10.26226/morressier.5cf632c0af72dec2b0554738Review of how expectations and the wording of warnings shape side effects and treatment adherence.the mechanism, reviewedtitle and year found
Abegaz et al., Medicine, 2017 doi:10.1097/md.0000000000005641Systematic review of non-adherence to blood-pressure drugs worldwide.size of the adherence gaptitle and year found

Closest prior work

The nocebo studies are mostly statin and high-income. The searches below look for a trial that tests expectation framing on blood-pressure drug adherence in low- and middle-income primary care.

The prior-work search was unavailable at the last check, so nothing is claimed about whether this has been tried. It reruns daily.

Benefit and cost

Estimated benefit: 1.05 WELLBYs per USD 1,000 (middle estimate; 5% to 95% range 0.1 to 6.58), counting side effects and spill-overs. Direct effect only: about USD 111 to 2,000 per healthy year of life gained. Chance the net effect is positive: 98%.

100% of this estimate rests on assumptions or weak evidence (grades C and D), not on a measured result for this combination. USD 5,000 for about 10,000 patients on treatment across 20 clinics: script design, one training session per clinic, printed cards (assumption). The pilot below exists to replace these assumptions with measurements.

For scale, the catalogue's cash-transfer entry is 7.55 WELLBYs per USD 1,000, from a published analysis. WELLBYs are one common measure, not the only value of an intervention. How the estimate is made.

Links in the estimate and how well each is sourced
LinkKindGradeSource
Years of healthy life gained (DALYs): 250 to 750 more patients still on treatment out of 10,000, each worth 0.01 to 0.06 DALY a yeardirectDassumption: 25% baseline stopping, 10-30% relative reduction from framing; DALY value per retained patient-year as in the barbershop entry
Real side effects under-reported (WELLBYs lost per DALY gained)unintendedDassumption

How to do it

Who: National hypertension programmes using WHO HEARTS, primary-care trainers, pharmacist associations.

What it takes: A one-page counselling script, an hour of nurse training, a printed card for the patient, and a question at refill visits that records why anyone stopped.

Cheapest first test: 20 clinics in one district, randomised 10 and 10 within a protocol that already runs. Intervention clinics use the script at the first prescription and at each refill. Primary outcome: share of new patients still collecting drugs at 6 months, from refill records. Safety outcome: serious adverse events reported to the clinic, to confirm that honest framing does not hide real harm. Stop rule: the pilot fails if retention at 6 months is not at least 5 points higher, or if serious events are higher in intervention clinics.

What could go wrong

  • The script could be read as dismissing a real reaction; the pilot has patients flag any symptom for a clinician anyway.
  • Counselling time is scarce; the script is meant to replace, not add to, the standard warning.
  • Refill records may not capture patients who switch to another pharmacy.

The nocebo evidence is strongest for statins, not blood-pressure drugs, and for patients in rich countries. Framing might reduce honest reporting of a real adverse effect, which is why the pilot measures serious events. The size of the effect on retention is unknown until a trial runs.

Machine-readable: JSON. Related catalogue entries: hypertension. Found an error? Tell us.